Regeneron, Roche Launch Major US Expansion Plans to Meet Growing Demand for Biologics and Innovation
With combined investments exceeding $53 billion, both companies are deepening their US presence through expanded biologics production, gene therapy capabilities, and next generation R&D centers.
Image Credit: Adobe Stock Images/vstudio
Regeneron and Roche have both individually announced multi-billion dollar investments to significantly expand manufacturing and R&D infrastructure in the United States. Together, the companies will invest more than $53 billion over the next decade, with initiatives spanning large-scale biologics production, advanced gene therapy manufacturing, AI-driven research, and next-generation therapeutic development. These moves, aimed at meeting escalating global demand and accelerating pipeline delivery, follow recent similar announcements from Novartis, Biogen, and Johnson & Johnson, as more companies reestablish US manufacturing capabilities with the looming threat of pharmaceutical tariffs from the Trump administration.1,2
Regeneron
Regeneron announced a major expansion of its biologics manufacturing capabilities through a new partnership with FUJIFILM Diosynth Biotechnologies. According to the company, the deal will nearly double its large-scale manufacturing capacity in the United States through the use of Fujifilm’s facility in Holly Springs, North Carolina.1
“Regeneron is an American success story, with over 80% of our workforce and assets in the United States. and all of our FDA-approved medicines invented in our New York laboratories,” said Leonard Schleifer, MD, PhD, board co-chair, president, chief executive officer, Regeneron, in a press release. “Our innovative approach has filled our commercial and clinical pipeline with important new medicines and driven a need for even more manufacturing capacity to fulfill the promise of our science. We are meeting this need through increased investment in New York and North Carolina. We are proud to advance biotech innovation, which directly improves the health of people around the globe, while generating economic growth and high-paying jobs for America itself.”
The ten-year partnership, valued at over $3 billion, is expected to complement Regeneron’s ongoing infrastructure growth, including a $3.6 billion expansion at its Tarrytown, NY, campus; a new fill/finish facility in Rensselaer, NY; and a recent acquisition of a one million square-foot site in Saratoga Springs, NY for production support. The deal is also expected to create approximately 1,000 full-time, high-skill jobs.1
“Partnering with Regeneron, a global leader in biotechnology and scientific innovation, is a true honor for us, as we bring together our exceptional teams and shared vision to make transformative medicine accessible to patients,” said Lars Petersen, president, CEO, FUJIFILM Diosynth Biotechnologies, in the press release. “We are honored that Regeneron has the trust and confidence in our teams’ ability to deliver capacity faster, ensuring continuity of supply for patients in need.”
Roche
Roche announced that it will invest $50 billion in the United States over the next five years with the goal of enhancing pharmaceutical and diagnostics operations. This includes expanding manufacturing and distribution capabilities across multiple states, building a new gene therapy facility in Pennsylvania, and establishing a 900,000-square-foot plant dedicated to weight loss medicines. Additionally, the company is expected to construct a continuous glucose monitoring facility in Indiana and open a new AI-driven R&D center in Massachusetts focused on cardiovascular, renal, and metabolic research.
The investment is expected to create over 12,000 new jobs, including 1,000 at the new and expanded facilities.2
“Roche is a Swiss company with a strong heritage in more than 130 countries globally,” said Thomas Schinecker, CEO, Roche Group, in a press release. “Today’s announced investments underscore our long-standing commitment to research, development and manufacturing in the US. We are proud of our 110-year legacy in the United States which has been a key driver for jobs, innovation and the creation of intellectual property in the US, across both our Pharmaceutical and Diagnostics Divisions. Our investments of USD 50 billion over the next five years will lay the foundation for our next era of innovation and growth, benefiting patients in the US and around the world.”
References
1. Regeneron Announces New Investment in Manufacturing of its Industry-Leading Biologic Medicines. Regeneron. April 22, 2025. Accessed April 22, 2025. https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-new-investment-manufacturing-its-industry
2. Roche to invest USD 50 billion in pharmaceuticals and diagnostics in the United States over the next five years. Roche. April 21, 2025. Accessed April 22, 2025. https://www.roche.com/media/releases/med-cor-2025-04-22
Cell and Gene Therapy Check-in 2024
January 18th 2024Fran Gregory, VP of Emerging Therapies, Cardinal Health discusses her career, how both CAR-T therapies and personalization have been gaining momentum and what kind of progress we expect to see from them, some of the biggest hurdles facing their section of the industry, the importance of patient advocacy and so much more.
